BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 21617522)

  • 1. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
    Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
    Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
    Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
    Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 testing in gastric and gastroesophageal adenocarcinomas.
    Vakiani E
    Adv Anat Pathol; 2015 May; 22(3):194-201. PubMed ID: 25844677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.
    Koopman T; Louwen M; Hage M; Smits MM; Imholz AL
    Am J Clin Pathol; 2015 Feb; 143(2):257-64. PubMed ID: 25596252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
    Treacy AD; Karamchandani JR; Streutker CJ; Grin A
    Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
    Nadaf AS; Rani H; Dinesh US
    Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
    Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
    Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 testing in gastric cancer.
    Albarello L; Pecciarini L; Doglioni C
    Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 testing in gastric cancer: a practical approach.
    Rüschoff J; Hanna W; Bilous M; Hofmann M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
    Mod Pathol; 2012 May; 25(5):637-50. PubMed ID: 22222640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
    Shan L; Ying J; Lu N
    Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis.
    Jeung J; Patel R; Vila L; Wakefield D; Liu C
    Arch Pathol Lab Med; 2012 Jun; 136(6):610-7. PubMed ID: 22646266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
    Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
    Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.
    Jørgensen JT
    World J Gastroenterol; 2014 Apr; 20(16):4526-35. PubMed ID: 24782605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
    Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population.
    Roy PS; Nyodu T; Hazarika M; Saikia BJ; Bhuyan C; Inamdar A; Nyuthe CW; Borthakur B; Sharma JD
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1139-1145. PubMed ID: 31030487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Bang YJ; Van Cutsem E; Feyereislova A; Chung HC; Shen L; Sawaki A; Lordick F; Ohtsu A; Omuro Y; Satoh T; Aprile G; Kulikov E; Hill J; Lehle M; Rüschoff J; Kang YK;
    Lancet; 2010 Aug; 376(9742):687-97. PubMed ID: 20728210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas.
    Nielsen SL; Nielsen S; Vyberg M
    Appl Immunohistochem Mol Morphol; 2017; 25(5):320-328. PubMed ID: 27801737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
    Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
    Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma.
    Jin Z; Holubek M; Sukov WR; Sattler CA; Wiktor AE; Jenkins RB; Wu TT; Yoon HH
    Am J Clin Oncol; 2019 Feb; 42(2):190-195. PubMed ID: 30516569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.